SLP Form 4: Director Acquires 2,074 Shares, Sells 867 at $12.93

Q: How many Simulations Plus (SLP) shares did Director Lisa LaVange receive?

She was granted 2,074 common shares under the 2021 Equity Incentive Plan.

Q: What price did LaVange sell her SLP shares for?

The 867 shares were sold in a single transaction at $12.93 per share.

Q: How many SLP shares does LaVange own after the transactions?

Her direct beneficial ownership stands at 9,930 common shares .

Q: Did the Form 4 report any derivative securities for SLP?

No. No derivative securities were reported in this filing.

[144] Twist Bioscience Corporation SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

144

Rhea-AI Filing Summary

Simulations Plus, Inc. (SLP) 鈥� Form 4 insider filing

Director Lisa LaVange disclosed two transactions on 08/01/2025:

Equity grant: 2,074 common shares awarded under the 2021 Equity Incentive Plan at a deemed price of $0, lifting her stake to 10,797 shares.
Rule 10b5-1 sale: 867 common shares sold at $12.93 per share in a single automatic trade, trimming direct ownership to 9,930 shares.

No derivative securities were involved, and the filing was executed by attorney-in-fact Daniel Hoeft on 08/04/2025.

Positive

Director received 2,074 shares as equity compensation, modestly increasing alignment with shareholder interests.

Negative

Director disposed of 867 shares at $12.93, reducing her direct stake to 9,930 shares.

Insights

TL;DR: Minor director sale offset by stock grant; negligible net ownership change鈥攊mpact appears neutral.

The filing shows Ms. LaVange received 2,074 shares as routine board compensation and subsequently sold 867 shares at $12.93 via a pre-set Rule 10b5-1 plan. Post-trade direct holdings stand at 9,930 shares, down only 8% from the intra-day peak of 10,797. No derivatives or unusual activity are reported. Given the modest size relative to her total stake and lack of material information about company operations, the market impact should be limited.

08/04/2025 - 04:21 PM

144: Filer Information

Filer CIK

Filer CCC

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

Common

Fidelity Brokerage Services LLC
900 Salem Street
Smithfield RI 02917

186

5275.72

59916141

08/04/2025

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

Common

08/01/2025

Restricted Stock Vesting

Issuer

186

08/01/2025

Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds

Robert Werner
681 Gateway Blvd
South San Francisco CA 94080

Common

05/05/2025

162

6099.46

Robert Werner
681 Gateway Blvd
South San Francisco CA 94080

Common

05/21/2025

242

7198.87

Robert Werner
681 Gateway Blvd
South San Francisco CA 94080

Common

05/23/2025

839

23263.88

Robert Werner
681 Gateway Blvd
South San Francisco CA 94080

Common

06/06/2025

225

7143.66

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Source:

FAQ

How many Simulations Plus (SLP) shares did Director Lisa LaVange receive?

She was granted 2,074 common shares under the 2021 Equity Incentive Plan.

What price did LaVange sell her SLP shares for?

The 867 shares were sold in a single transaction at $12.93 per share.

How many SLP shares does LaVange own after the transactions?

Her direct beneficial ownership stands at 9,930 common shares.

Were the sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was automatically executed pursuant to a Rule 10b5-1 plan.

Did the Form 4 report any derivative securities for SLP?

No. No derivative securities were reported in this filing.

AG真人官方

[144] Twist Bioscience Corporation SEC Filing

Insights

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Simulations Plus (SLP) shares did Director Lisa LaVange receive?

What price did LaVange sell her SLP shares for?

How many SLP shares does LaVange own after the transactions?

Were the sales made under a Rule 10b5-1 trading plan?

Did the Form 4 report any derivative securities for SLP?

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

AG真人官方

Trending News

[144] Twist Bioscience Corporation SEC Filing

Insights

Securities Analyst neutral

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Simulations Plus (SLP) shares did Director Lisa LaVange receive?

What price did LaVange sell her SLP shares for?

How many SLP shares does LaVange own after the transactions?

Were the sales made under a Rule 10b5-1 trading plan?

Did the Form 4 report any derivative securities for SLP?

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data